NCEL

NewcelX Ltd

Feb 27 • 04:00PM ET

2.90

+0.03 1.05 %

Healthcare • Biotechnology • Switzerland • NASD

Peers: VRNA OCUL HYPD RLMD GNPX ARDX ALDX MNOV ANVS

Index	-	P/E	-	EPS (ttm)	-17.34	Insider Own	10.75%	Shs Outstand	4.56M	Perf Week	7.41%
Market Cap	13.22M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	4.07M	Perf Month	9.85%
Enterprise Value	10.21M	PEG	-	EPS next Q	-	Inst Own	0.01%	Short Float	2.62%	Perf Quarter	-17.14%
Income	-6.21M	P/S	-	EPS this Y	-	Inst Trans	-94.27%	Short Ratio	0.94	Perf Half Y	-86.94%
Sales	0.00M	P/B	0.43	EPS next Y	-	ROA	-78.31%	Short Interest	0.11M	Perf YTD	52.63%
Book/sh	6.79	P/C	4.31	EPS next 5Y	-	ROE	-	52W High	30.80 -90.58%	Perf Year	-84.07%
Cash/sh	0.67	P/FCF	-	EPS past 3/5Y	56.71% 33.06%	ROIC	-215.58%	52W Low	1.89 53.44%	Perf 3Y	-99.48%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.48% 8.14%	Perf 5Y	-99.75%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	77.07%	Oper. Margin	-	ATR (14)	0.20	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.77	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	55.53	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.77	EPS Q/Q	46.08%	SMA20	4.72%	Beta	0.14	Target Price	1600.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	12.41%	Rel Volume	0.03	Prev Close	2.87
Employees	3	LT Debt/Eq	0.00	Earnings	-	SMA200	-78.72%	Avg Volume	113.64K	Price	2.90
IPO	Jan 29, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	0.00% -	Trades		Volume	3,181	Change	1.05%

Feb-12-26 07:00AM	NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy (PR Newswire)
Jan-29-26 07:00AM	NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences (PR Newswire)
Jan-12-26 07:00AM	NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression (PR Newswire) +13.70%
Jan-05-26 07:00AM	NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board (PR Newswire) +6.70%
Dec-11-25 07:00AM	NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China (PR Newswire) -21.83%
07:00AM	Loading…
Nov-17-25 07:00AM	NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute (PR Newswire)
Nov-06-25 07:00AM	NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board (PR Newswire) -11.70%
Nov-04-25 07:00AM	NewcelX CEO Issues Letter to Shareholders (PR Newswire) +10.02%
Nov-03-25 08:25AM	NewcelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd. (PR Newswire) -29.49%
Oct-30-25 04:15PM	NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger (PR Newswire)
07:00AM	NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs (PR Newswire)
Oct-29-25 07:00AM	NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger (PR Newswire) -29.52%
06:00AM	NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem (PR Newswire)
03:53AM	NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares (PR Newswire)
Oct-27-25 07:00AM	NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies (PR Newswire)
06:01AM	Loading…
Oct-23-25 06:01AM	NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025 (PR Newswire) -16.98%
Sep-30-25 07:00AM	NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting (PR Newswire) -25.31%
Sep-10-25 06:00AM	Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger (PR Newswire) +6.70%
Sep-04-25 07:38AM	NLS Pharmaceutics and Kadimastem announce a Hong Kong Patent Covering Cell-Selection and Enrichment Technology for IsletRx for Diabetes Patients (PR Newswire)
Jul-17-25 07:00AM	NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy (PR Newswire)
Jun-30-25 07:00AM	NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing (PR Newswire)
Jun-16-25 07:00AM	NLS Pharmaceutics CEO Issues Letter to Shareholders (PR Newswire)
May-21-25 07:30AM	NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting (PR Newswire)
Apr-15-25 09:00AM	NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models (PR Newswire)
Mar-31-25 09:10AM	NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement (ACCESSWIRE) +18.46%
Mar-10-25 07:00AM	NLS Pharmaceutics CEO Issues Letter to Shareholders (PR Newswire)
Feb-27-25 07:00AM	NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform (PR Newswire)
Feb-25-25 09:05AM	Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment (PR Newswire)
Feb-10-25 07:30AM	NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies (PR Newswire) +37.43%
Jan-31-25 07:30AM	Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics (PR Newswire) +25.76%
07:30AM	Loading…
Jan-30-25 07:30AM	NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting (PR Newswire)
Jan-28-25 07:30AM	NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence (PR Newswire)
Jan-16-25 09:32AM	Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS (PR Newswire)
Jan-09-25 08:28AM	NLS Pharmaceutics and Kadimastem Advance Merger Plans with $500,000 Fundraising (TipRanks)
Jan-08-25 07:42AM	NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market Share Price as of Jan 6, 2025 (PR Newswire) +16.99%
Dec-30-24 07:30AM	NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger (PR Newswire) +49.45%
Dec-19-24 07:30AM	NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment (ACCESSWIRE) +19.00%
Dec-12-24 07:45AM	NLS Pharmaceutics expects to close Kadimastem merger by end of January (TipRanks)
Dec-11-24 07:30AM	NLS Pharmaceutics CEO Issues Letter to Shareholders (ACCESSWIRE)
Dec-04-24 01:15PM	NLS Pharmaceutics Ltd. Announces Pricing of Private Placement of up to $1 Million at a 15% Premium to the Market (PR Newswire)
Dec-03-24 07:40AM	NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders (ACCESSWIRE) -11.22%
Nov-18-24 07:30AM	NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders (ACCESSWIRE)
Nov-05-24 07:31AM	NLS Pharmaceutics, Kadimastem enter definitive merger agreement (TipRanks) -7.97%
Nov-04-24 07:00AM	NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement (ACCESSWIRE) +21.94%
Oct-28-24 07:00AM	NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements (ACCESSWIRE)
Oct-21-24 07:00AM	NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence (ACCESSWIRE) -10.19%
Oct-19-24 04:57PM	NLS Pharmaceutics Sees Reduced Losses Amid Financial Challenges (TipRanks)
Oct-15-24 07:00AM	NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules (ACCESSWIRE)
Sep-25-24 08:00AM	NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split (ACCESSWIRE)
Jul-29-24 11:58AM	Tivic Health Systems (TIVC) Stock Pops Another 39% (InvestorPlace) +23.05%
07:00AM	NLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to Merge (ACCESSWIRE)
Jun-28-24 09:00AM	NLS Pharmaceutics Announces Registered Direct Offering (ACCESSWIRE) -9.62%
Jun-27-24 08:00AM	NLS Pharmaceutics Announces Promising Preclinical Results for Parkinson's Disease Treatments (ACCESSWIRE) +31.43%
Jun-25-24 08:30AM	Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements (ACCESSWIRE) -5.61%
Jun-20-24 09:47AM	PLTR Stock: Palantir Bags New Partnership With ARPA-H for AI/ML (InvestorPlace) -30.80%
08:38AM	Why Is NLS Pharmaceutics (NLSP) Stock Down 23% Today? (InvestorPlace)
07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
Jun-18-24 07:54AM	Why Is NLS Pharmaceutics (NLSP) Stock Up 163% Today? (InvestorPlace) +82.13%
07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
Jun-11-24 08:30AM	NLS Pharmaceutics Announces Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (DOXA) (ACCESSWIRE) +6.33%
May-28-24 08:00AM	NLS Pharmaceutics Reports Positive Results from Study KO-874 on Mazindol's Neuroprotective Effects in Narcoleptic-like Rat Model (ACCESSWIRE)
May-24-24 05:00PM	NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq (ACCESSWIRE)
Apr-19-24 05:00PM	NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing (ACCESSWIRE)
Mar-22-24 04:30PM	NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering (ACCESSWIRE) +5.94% -8.06%
Mar-20-24 01:40PM	NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering (ACCESSWIRE) -41.72%
07:30AM	NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform (ACCESSWIRE)
Mar-14-24 08:00AM	NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event (ACCESSWIRE)
Mar-11-24 07:00AM	Nasdaq Accepts NLS Pharmaceutics' Plan to Regain Listing Compliance (ACCESSWIRE) +8.97%
Feb-23-24 07:30AM	NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq (ACCESSWIRE)
Jan-12-24 04:30PM	Notice of Deficiency with Nasdaq Continued Listing Requirements (ACCESSWIRE) -7.88%
Dec-29-23 04:30PM	NLS Pharmaceutics CEO Issues Letter to Shareholders (ACCESSWIRE) +16.60%
Dec-04-23 09:06AM	Why Is NLS Pharmaceutics (NLSP) Stock Down 24% Today? (InvestorPlace) -8.20%
07:21AM	10 Best Debt Free Penny Stocks To Buy Now (Insider Monkey)
Dec-01-23 07:30AM	NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc. (ACCESSWIRE) +45.27%
Nov-28-23 07:30AM	NLS Pharmaceutics Announces Election of Additional Board Members (ACCESSWIRE)
Nov-27-23 08:30AM	NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit: Deep Dive into Narcolepsy and Idiopathic Hypersomnia (ACCESSWIRE)
Nov-16-23 08:00AM	NLS Pharmaceutics Announces Selection of Strategic Partner and Securing a Bridge Loan (ACCESSWIRE) -34.44%
Oct-25-23 04:30PM	NLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification (ACCESSWIRE) -7.14%
Oct-19-23 05:00PM	NLS Pharmaceuticals to Reschedule Company Update on Strategic Discussions (ACCESSWIRE) -15.03%
Oct-12-23 09:40AM	NLS Pharmaceutics Announces Company Update on Strategic Partnerships (ACCESSWIRE) -12.63%
Aug-28-23 07:30AM	NLS Pharmaceutics CEO Issues Letter to Shareholders (ACCESSWIRE) +9.63%
Jul-03-23 07:00AM	NLS Pharmaceutics to Proceed with Phase 3 Clinical Program (AMAZE) for Mazindol ER for the Treatment of Narcolepsy Following FDA Review and IRB Approval of the Full Study Protocol (ACCESSWIRE) +9.09%
Jun-30-23 04:05PM	NLS Pharmaceutics Releases the Results from its Annual General Meeting (ACCESSWIRE) +19.57%
08:00AM	NLS Pharmaceutics Company Update and Webcast Today Postponed (ACCESSWIRE)
Jun-19-23 07:30AM	CORRECTION FROM SOURCE: NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest (ACCESSWIRE)
07:10AM	NLS Pharmaceutics Announces Company Update Webcast (ACCESSWIRE)
Jun-15-23 08:30AM	NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest (ACCESSWIRE) +6.01%
07:30AM	NLS Pharmaceutics Announces Company Update Webcast (ACCESSWIRE)
Jun-14-23 07:30AM	NLS Pharmaceutics Announces Positive Safety Data From In Vitro CYP450 and Transporter Mediated Drug-Drug Interaction Studies of Mazindol (ACCESSWIRE)
May-08-23 08:30AM	NLS Pharmaceutics Appoints Keith Harrison Dewedoff as Interim Chief Financial Officer (ACCESSWIRE)
May-04-23 08:30AM	NLS Pharmaceutics Presents Latest Clinical and Preclinical Data at SLEEP 2023 (ACCESSWIRE) -5.18%
May-02-23 08:45AM	NLS Pharmaceutics Receives Green Light from the U.S. FDA to Proceed with Phase 3 Clinical Program (AMAZE) for Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy (ACCESSWIRE) +8.59%
Apr-25-23 08:50AM	NLS Pharmaceutics Presents Latest Preclinical Pipeline Data at American Society of Clinical Psychopharmacology (ACCESSWIRE)
Mar-27-23 08:30AM	NLS Pharmaceutics Announces Open Label Extension Study Six-Month Data for Quilience(R) (Mazindol ER) in the Treatment of Narcolepsy Type 1 and Type 2 (ACCESSWIRE) +7.72%
Mar-01-23 08:30AM	NLS Pharmaceutics to Present at the 35th Annual Roth Conference (ACCESSWIRE)
Jan-30-23 08:30AM	NLS Pharmaceutics Announces Completion of Open Label Extension Study with Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy (ACCESSWIRE)
Jan-25-23 08:30AM	NLS Pharmaceutics Regains Compliance with Nasdaq Stockholders' Equity Requirement (ACCESSWIRE)
Jan-23-23 08:30AM	NLS Pharmaceutics Announces New In-Vitro Data Reconfirming Quilience's(R) (Mazindol ER) Unique Dual Mechanism of Action Involving Significant Orexin-2 Receptor Activity (ACCESSWIRE)
Jan-12-23 08:30AM	NLS Pharmaceutics Announces an R&D Update Webcast to Review the Company's Growing Portfolio of Pre-Clinical Compounds (ACCESSWIRE)
08:15AM	NLS Pharmaceutics Announces Compliance with Nasdaq Bid Price Requirement (ACCESSWIRE)

NewCelX Ltd. is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company is headquarter in Kloten, Switzerland.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NCEL

NewcelX Ltd

Upgrade your FINVIZ experience